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 Forensic toxicology is a branch of science that involves the analysis of drugs and 
other substances in biological fluids and tissues such as blood, urine, and oral fluid to aid 
medical or legal investigation of death, poisoning, and drug use. Due to the various 
components of different matrices, efficient and effective sample preparation techniques are 
necessary for reliable and accurate analysis. Following sample clean-up, a sensitive, 
specific, and robust method is ideal for consistent detection, identification, and quantitation 
of analytes. With the rise of drug abuse, there is a growing need to develop a single method 
that can target multiple classes of drugs quickly and effectively. 
This study validated two different sample preparation techniques for the detection 
and quantitation of six drug classes comprised of twenty-three drugs and metabolites in 
oral fluid. The drug classes were as follows: amphetamines, local anesthetics, opioids, 
hallucinogens, antidepressants, and novel psychoactive substances (NPS). Amphetamines 
used were amphetamine, methamphetamine, 3,4-methylenedioxyamphetamine (MDA), 
3,4-methylenedioxy-N-ethylamphetamine (MDEA), and 3,4-
methylenedioxymethamphetamine (MDMA). Local anesthetics contained 
benzoylecgonine (BZE), cocaine, and lidocaine. Opioids included codeine, methadone, 
morphine, 6-monoacetylmorphine (6-MAM), fentanyl, and oxycodone. Hallucinogens 
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included lysergic acid diethylamide (LSD) and phencyclidine (PCP). Antidepressants were 
amitriptyline, citalopram, fluoxetine, and trazodone. Lastly, NPS included ethylone, α-
pyrrolidinopentiophenone (α-PVP), and 2,5-dimethoxy-4-iodophenethylamine N-(2-
methoxybenzyl) (25I-NBOMe). Supported liquid extraction (SLE) and solid phase 
extraction (SPE) were assessed followed by confirmatory analysis by liquid 
chromatography (LC)-tandem mass spectrometry (MS/MS). 
Both methods were validated according to guidelines in the Standard Practices for 
Method Validation in Forensic Toxicology set by the American Academy of Forensic 
Science (AAFS) Standards Board (ASB). Parameters assessed include calibration model, 
bias, precision, limit of detection (LOD), limit of quantitation (LOQ), dilution integrity, 
ion suppression/enhancement, interference studies, and stability. Matrix recovery was 
added as another parameter. All calibration models were 0.99 or greater and all compounds 
were stable for at least 72 hours. Bias, precision, LOD, LOQ, dilution integrity, and 
interferences were similar between both methods. SLE yielded slightly better LOD and 
LOQ values. SLE had greater values of matrix recovery as well as lower levels of ionization 
suppression/enhancement.  
  Overall, SLE was determined to be the better method of sample preparation for this 
panel of drugs in oral fluid. Not only did it yield higher values for several of the parameters 
assessed but it also was more efficient (1 hour versus 2 hours) while using less solvent. 
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 Drugs are used for a myriad of reasons: to relieve pain, to treat or cure illnesses, to 
promote well-being, or to produce other effects. Upon ingestion, a drug is capable of 
inducing a physiological change to the body.1 Desired effects upon consumption can lead 
to abuse, increasing prevalence in forensic casework. Forensic toxicology is the analysis 
of bodily fluids such as blood, urine, vitreous humor and tissues for toxic substances which 
can include drugs and poisons.2 For confirmatory testing, the process begins with sample 
preparation. There are several techniques that range from simple to rigorous clean-up of 
the matrix. Volatile substances can be separated from an aqueous matrix by heating it in a 
sealed container.2 Protein precipitation uses inorganic acids or solvents such as tungstic 
acid, acetone, chloroform, or methanol to physically remove proteins from the matrix.2,3 
Supported liquid extraction and solid phase extraction are more robust methods of sample 
preparation that can remove not only proteins but also other compounds including drugs.2 
Certain compounds may extract better with one technique over another. Certain techniques 
can target a diverse group of compounds while others are more specific. Choosing the ideal 
sample preparation technique for the situation can lead to successful analysis. 
  For this research, two different sample preparation techniques were assessed: 
supported liquid extraction and solid phase extraction. SPE is a commonly used and well-
established technique while SLE is recent but powerful technique for sample extraction. 
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Both techniques can target multiple classes of drugs while removing the matrix 
components. 
 Typical biological fluids analyzed for forensic toxicology are blood and urine. This 
project explored oral fluid as an alternative matrix. Oral fluid (saliva) is produced by 
mainly three glands in the mouth: the parotid, submaxillary, and sublingual.4 It is a much 
cleaner matrix when compared to blood with a low protein content of approximately 0.3%.4 
The collection of oral fluid is not as invasive as collection of blood or urine. Unlike urine, 
it also cannot be substituted by common liquids or chemicals. Oral fluid analysis has 
become a growing area of interest for testing drugs of abuse. Screening and confirmation 
testing has been done using oral fluid in five Australian states.5 According to the Substance 
Abuse and Mental Health Services Administration (SAMHSA), federal agencies can 
collect oral fluid as an alternative specimen when someone is unable to provide a sufficient 
urine specimen.6 
 Collection of oral fluid can be done with several different methods. A person can 
simply expectorate or spit into a collection tube but this may result in a viscous fluid with 
food contaminants.4 Commercial collection devices that use a diluent such as an extraction 
buffer can help create an easier matrix to work with.4 Certain commercial devices may 
have better recovery for specific drugs or classes of drugs than others. Oral fluid production 
can be stimulated by agents such as gum or citric acid which can also affect the pH or 
concentration of the drug in the mouth.4 Additionally, certain drugs can also increase or 
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decrease oral fluid production such as codeine, amphetamines, and antidepressants.4 
Ultimately, it can depend on the individual as well. 
 The concentration of drugs in oral fluid is reported to be similar to that of blood 
and plasma.4,7 The detection of drugs in oral fluid can be affected by different factors such 
as pKa, physical size, degree of protein binding, and lipophilicity of the drug.8 The most 
common method of drug transport from blood to oral fluid is passive diffusion.9 Typically, 
the parent drug is found rather than the metabolite because it is more lipid soluble.8 Its 
lipophilicity allows the parent drug to diffuse through the capillary and acinar cell 
membranes into the oral fluid.8 Drugs that are weak bases are found in higher 
concentrations in oral fluid than in plasma due to ion trapping.10 Concentrations of specific 
drugs in oral fluid will vary between each class and type since they have their own unique 
structures that affect size, polarity, and lipophilicity. In a study performed by Verstraete, 
amphetamine was detectable for 20 to 50 hours while cocaine was only found for 5 to 12 
hours in oral fluid.11  
 This project included twenty-three different drugs for extraction by SLE and SPE. 
The classes of drugs included amphetamines, local anesthetics, opioids, hallucinogens, 
antidepressants, and novel psychoactive substances. It is important to be able to test for 
multiple drugs in one method. Abusers may be taking multiple illicit drugs at once. Some 
may be ingesting prescription drugs as well as illicit drugs. Victims of sexual assault can 
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have multiple drugs in their system. In forensic toxicology casework, testing for multiple 
drugs at once can expedite analysis and prevent or aid in backlogs.  
1.2. Drugs 
1.2.1 Amphetamines  
Amphetamines are a group of synthetic drugs derived from phenethylamines, 
which are structurally similar to adrenaline.12 These drugs illicit varying degrees of 
sympathomimetic activity when ingested by mimicking the actions of endogenous 
neurotransmitters that stimulate the sympathetic nervous system or by affecting the release 
of endogenous neurotransmitters or inhibiting their reuptake.2 These central nervous 
stimulants (CNS) were first designed for medicinal use to treat narcolepsy and depression 
but their ability to alleviate fatigue, elevate mood, increase confidence, and produce 
euphoria resulted in their abuse.2 This class of drugs include amphetamine, 
methamphetamine, and their methylenedioxy analogs: 3,4-methylenedioxyamphetamine, 
3,4-methylenedioxymethamphetamine, and 3,4-methylenedioxy-N-ethylamphetamine.2  
Currently, amphetamines are used clinically to treat exogenous obesity through 
appetite suppression, attention deficit disorder, and narcolepsy.2 The United Nations Office 
on Drugs and Crime (UNODC) World Drug Report 2019 show the steady yearly rise of 
amphetamine use since 2002 with methamphetamine as the drug of choice.13 According to 
the 2001-2017 National Forensic Laboratory Information System (NFLIS) Special Report 
of Methamphetamine, cocaine and cannabis use have declined through the years while 
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methamphetamine use has increased.14 Similarly, MDA and MDMA have become more 
popular as drugs of abuse due to their hallucinogenic and psychoactive properties.2  
1.2.2. Local Anesthetics 
 Local anesthetics interrupt neural conductivity by inhibiting the influx of sodium 
ions through channels or ionophores within neuronal membranes, resulting in loss of senses 
and motor function.15 All local anesthetics contain a lipophilic aromatic ring, intermediate 
ester or amide linkage, and tertiary amine, which contribute to their distinct clinical 
properties.15 Lidocaine and cocaine are examples of local anesthetics while 
benzoylecgonine is a major metabolite of cocaine.2 Cocaine’s limited clinical use is as 
topical administration as a local anesthetic in ear, nose, and throat surgery and in 
ophthalmologic procedures.2 Lidocaine is the most widely used local anesthetic through 
topical use and intravenous injection.15,16  
 Cocaine is a natural alkaloid isolated from the Erythroxylon coca plant, mainly 
found in the South American Andes.2 It is abused by users to experience effects such as 
intense euphoria, heightened sexual excitement, psychic energy, and self-confidence.2 
Although medicinally used as a local anesthetic, illicit cocaine is used as a stimulant and 
can be found in two forms: hydrochloride salt and freebase (crack).2 The purity of salt form 
is generally higher than 50% and can be cut with compounds to increase bulk such as 
mannitol, lactose, and sucrose or to stimulate the effects of cocaine such as caffeine, 
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ephedrine, lidocaine, and procaine.2 According to the NFLIS-Drug 2018 Annual Report, 
cocaine is one of the top five most abused drugs.17 
1.2.3. Opioids 
 Opioid is a general term for alkaloids derived from the opium poppy, Papaver 
somniferum, their synthetic analogues, and compounds synthesized in the body that bind 
to the opioid receptors found in the brain.18 Opioid use results in an analgesic effect by 
blocking the transmission of painful stimuli as well as a state of euphoria.2 The primary 
use for opioids is pain management for postoperative analgesia and chronic pain associated 
with cancer or other terminal illnesses.2 Other uses include cough suppressant, sedation, 
and antidiarrheal; methadone can be used for detoxification and to lessen opioid 
withdrawal symptoms.2 Risks of opioid use include respiratory depression, hypothermia, 
seizure, hypotension, and coma.2 
Natural opioids include morphine and codeine, which can be found in the latex or 
milky substance from the poppy seed pod.1 Heroin, hydrocodone, and oxycodone, which 
are derived from morphine, codeine, and thebaine, respectively, are examples of semi-
synthetic opioids. 6-acetylmorphine is an active metabolite of heroin and can be detected 
in oral fluid.10,19 Synthetic opioids are designed to mimic the effects of naturally occurring 
opioids and include fentanyl and methadone.2 
1.2.4. Hallucinogens 
 Hallucinogens are drugs that can alter one’s perception of reality; they can also be 
referred to as psychedelic, psychotomimetic or psychotogen drugs.2 Although there are 
several classes of drugs that can cause illusion, hallucinations, or delusions, psychedelics 
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differ in that they can produce states of altered perception, thought, and feeling2. 
Hallucinogens, on the other hand, induce a heightened awareness of sensory input and 
diminished control over what is experienced.2  
 Phencyclidine is a dissociative anesthetic but it can also act as a stimulant, 
depressant, hallucinogen, and anesthetic depending on the dose, route of administration, 
personality of the individual, and genetic predisposition.2 At low doses, PCP can cause 
perspiration, agitated behavior, anxiety, and dissociation; at moderate doses, rage, 
insomnia, fever, amnesia and at high doses, hypertension, catatonia, coma, and death.2 
Although there is a decline in PCP use over the years, it is still one of the top twenty-five 
identified drugs in 2018 according to the NFLIS-Drug 2018 Annual Report.17  
 Lysergic acid diethylamide is a semi-synthetic drug created from lysergic acid and 
dimethylamine.1,2 Lysergic acid is an alkaloid found in the grain parasitized by the fungus 
Claviceps purpurea and the similar compound lysergic acid amide can be found in morning 
glory seeds and the Hawaiian baby wood rose; both can be used to synthesize LSD.2 LSD 
can illicit both physiological such as mydriasis, tachycardia, and hyperglycemia and 
psychological effects such as visual illusions and altered hearing.2  It is extremely potent 
with low microgram dosages leading to hallucinogenic “trips” that can last up to fifteen 
hours.20 Due to its potency, LSD is almost always diluted before ingestion; the colorless, 
odorless, and tasteless liquid can be impregnated onto blotter paper and microdots at 
dosages between 0.05 – 0.1 milligram (mg).2 In the 1950s, LSD was used clinically to treat 
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alcoholism, opioid addiction and sexual disorders but present day, it has no accepted 
medical use.2  
1.2.5. Antidepressants 
 Antidepressants are one of the most commonly prescribed drugs in the United 
States. In the United States alone, about nineteen million Americans suffer from 
depression.2 The use of antidepressants amongst adults eighteen years of age or older 
increased fivefold during 1988 – 1994 and 2005 – 2008.21 Antidepressants are primarily 
used to treat depression but they can also be used to treat eating disorders, panic disorders, 
posttraumatic stress disorders, anxiety, and chronic pain.2,21  
 Antidepressants can be classified into first-generation, second-generation, selective 
serotonin reuptake inhibitors (SSRIs) or third-generation.2 First-generation antidepressants 
include tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs).2,22 
TCAs all have a three-ring structure; amitriptyline is an example of a TCA.2 They act by 
preventing the reuptake of either norepinephrine or serotonin while MAOIs inhibit their 
metabolism.2  
Second-generation antidepressants such as trazodone do not have a similar basic 
structure but can work similarly to TCAs and also exhibit a sedating effect.2 In the United 
States, SSRIs such as citalopram and fluoxetine are the most prescribed class of 
antidepressants.2 They not only inhibit the reuptake of serotonin but also act on with a 
number of serotonin receptors.2 Unlike TCAs, they are not adrenergic, antihistaminic or 
anticholinergic and are better suited for most individuals.2 Third-generation 
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antidepressants include a number of chemically and pharmacologically different 
compounds.2  
1.2.6. Novel Psychoactive Substances 
 To achieve “legal highs,” novel psychoactive substances are created in an effort to 
evade the law. NPS are generally analogues or chemical derivatives of already controlled 
substances made to produce similar effects but they can also have completely new 
structures.22 They can include a variety of different classes of drugs such as synthetic 
cannabinoids, cathinones, phenethylamines, and opioids.23,24 Ethylone, α-
pyrrolidinopentiphenone, and 2,5-dimethoxy-4-iodophenethylamine N-(2-
methoxybenzyl) examples of NPS.   
 Ethylone and α-PVP are both synthetic cathinones, derived from the naturally 
occurring cathinone found in the khat plant (Catha edulis).23 Synthetic cathinones are β-
ketoamphetamines with structures similar to dopamine and MDMA; they can produce 
properties similar to amphetamine and interact with serotonin.25,26 They were originally 
synthesized to treat depression and anorexia but due to their severe side effects and abuse 
potential, only bupropion is used medicinally in the United States and Europe.26,27 The use 
of synthetic cathinones can lead to stimulant and hallucinogenic effects and are often used 
in replace of MDMA and cocaine.25 They also labeled as “bath salts,” “plant food,” 
“fertilizer,” or “not for human consumption.”25,26 As more regulations are put into place, 
the rise of NPS follows. In the NFLIS Special Report on Synthetic Cannabinoids and 
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Synthetic Cathinones, ethylone and α-PVP can both be found in the top twenty-five most 
frequently reported synthetic cathinones.28  
 25I-NBOMe is part of an expanding class of NBOMes, which have the addition of 
a 2-methoxybenzyl functional group to the nitrogen of the phenethylamine backbone.29 
They are mainly sued for their hallucinogenic properties and have a high affinity for the 
serotonin 5-HT2A receptor.30,31 The effects are similar to that of LSD and can be 
impregnated onto blotter paper.32 The drug can be taken sublingually, by insufflation, or 
through the buccal cavity.32 The use of 25I-NBOMe can lead to not only hallucinations but 
also tachycardia, hypertension, agitations, and seizures.29 A clinical effect of 25I-NBOMe 
that can lead to death is excited delirium, which is described as delirium with agitation, 
violence, hyperactivity, and hyperthermia.33 These effects can ultimately result in sudden 
cardiopulmonary arrest.33  
1.3. Sample Preparation 
1.3.1. Supported Liquid Extraction 
 Supported liquid extraction is a technique that isolate compounds based on their 
affinity between two immiscible solvents.34 It has a packed column made up of 
diatomaceous earth, which is a natural silica based sediment from under the sea.34 Due to 
its polar nature and large irregular surface area, it is an ideal material for analytes to adsorb 
onto.34 First, the sample should be prepared so that it is un-ionized. Then, it should be put 
onto the bed of the column and allowed to absorb completely. Next, a nonpolar organic 
solvent is applied to remove compounds of interest. Finally, pressure or vacuum can be 
applied to the column to push through all the eluent and collected for analysis. 
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1.3.2. Solid Phase Extraction 
Solid phase extraction utilizes solid particles to separate components of a sample 
or mixture.35 It was first developed during the 1960s and early 1970s but is still very 
popular to this day.2 Columns generally have a purified silica base with different chemical 
groups such as hydrocarbon chains, phenyl groups, or polar groups covalently bonded to 
it.2 Solvents are used to wash and elute the columns of the analyte of interest. First, the 
column must be conditioned with a number of solvents to wet the packing material. After, 
the sample can be loaded onto the column. Then solvents wash the column to rid of any 
unwanted compounds or materials. Finally, the analyte of interest can be eluted and 
prepared for analysis. SPE selectively allows certain molecules to bind to the packing 
material while eliminating carbohydrates, proteins, polar lipids, and other unwanted 
compounds from the final sample.2 
1.4. Instrumentation Theory 
1.4.1. Liquid Chromatography 
To accurately and reliably detect and identify an analyte of interest, samples should 
be relatively pure. Qualitative and quantitative analysis of a mixture can lead to the wrong 
conclusions. Liquid chromatography allows for the separation of components in a mixture 
based on its affinity to the mobile and stationary phase. The sample is dissolved and carried 
through a solid stationary phase by the liquid mobile phase.36 Compounds will be adsorbed 
onto the stationary phase. The LC column is tightly packed with solid material of varying 
size and composition. Compounds are separated based on their interactions with both the 
mobile and stationary phase. LC can be paired up with different types of detectors such as 
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ultraviolet-visible spectroscopy or mass spectrometry.36 The components of an LC are the 
mobile phase reservoir/pumps, pump, injector, column, and detector.36  
In an LC, separation does not always happen isocratically, which is the use of an 
unchanging mobile-phase.2 The mobile phase can be manipulated during the course of a 
run to improve chromatographic separation. The mobile phase is organic for normal phase 
separation while it is aqueous for reverse phase. Reverse phase is much more common for 
LC. Mixtures of solvents as well as gradients during the run can be utilized to aid in better 
separation. Commonly used solvents include water, methanol, acetonitrile, and 
tetrahydrofuran.2  
The first packing material was made up of silica or alumina and were very polar; 
this was called normal phase.2 Later, the packing material was further developed so that 
the silica base held chains of C18; now, they can not only hold various chain lengths of 
hydrocarbons but also different chemical groups.2  
Both mobile phase and stationary phase affect chromatographic separation. 
Molecules with a higher affinity towards the stationary phase travel more slowly while 
those with lower affinity will travel quickly, reaching the detector sooner. Additionally, the 
stationary phase particle size and column length can also impact separation.36 Smaller 
particles lead to an improvement in separation efficiency but results in higher pressure. A 
longer column gives an analyte more time to elute which could lead to better separation 
but can lead to broadening of peaks.  
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1.4.2. Mass Spectrometry 
 Mass spectrometry is a technique that relies on the ionization and 
subsequent fragmentation of an analyte in the gas phase.36 It can help identify a 
compound’s structure through mass data analysis. First, the analyte must be a gaseous ion. 
Based on its mass (m) to charge (z) ratio, it can be isolated through the manipulation of 
magnetic and electrostatic fields.2 The mass analyzer and detector can translate the ions 
into a signal that is read by the data system.2 The basic components of a mass spectrometer 
include the sample inlet, ion source, mass analyzer, detector, and vacuum system.2 The ion 
source, mass analyzer, and detector are kept under vacuum when in use.2  
Before a sample is introduced to the mass spectrometer after the LC, the liquid 
sample must be converted to the gas phase and ionized through atmospheric pressure 
ionization (API).2 Electrospray ionization (ESI) is the most common method of API.2 This 
technique has three main components: the nebulizer, desolvation assembly, and mesh 
electrode or repeller.2 A strong electric field is applied to the liquid sample, which results 
in the accumulation of charge and the breaking of the sample into highly charged droplets.37 
Heated nitrogen gas aid in converting the liquid sample into gas.2,36 As the solvent 
evaporates, droplets become smaller in size; repulsion forces between like charges break 
the surface tension of droplets and result in even smaller droplets.36 This process repeats 
until ions are formed. Ions are drawn to capillary due to a charge difference and are lead 
into the mass analyzer.2 ESI is a soft ionization technique, which results in more parent ion 
and less fragmentation.36 
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The quadrupole is the most common mass analyzer used in MS.  It consists of four 
parallel rods of hyperbolic section placed about a central axis.36,37 Two diagonal rods are 
connected to radio frequency (RF) while the other two are connected to direct current 
(DC).36 Specific RF and DC allow ions with a certain mass-to-charge ratio (m/z) to pass 
through the analyzer without touching the rods and to the detector.36  
Tandem mass spectrometry utilizes three quadrupoles in a series as the mass 
analyzer.2 The first (Q1) and third (Q3) quadrupoles act as mass spectrometers, utilizing 
both RF and DC; the second quadrupole (Q2), however, only uses RF and acts as a collision 
cell.37 Q1 allows only the parent ion to pass through.2,37 An inert gas causes collisions 
between gas molecules in Q2 to create fragments of the parent ion, known as product ions.2 
Product ions formed in Q2 move onto Q3, which can scan for all the ions or only allow 
specific ions to the detector.2 Tandem mass spectrometry can identify compounds with 
greater accuracy and reliability since it can isolate a single parent ion and its fragments.  
1.5. Research Objective 
 The purpose of this research is to compare two different sample preparation 
techniques for the detection and quantitation of twenty-three different drugs in oral fluid. 
The analytes of interest included amphetamines, local anesthetics, opioids, hallucinogens, 
antidepressants, and novel psychoactive drugs. The goal was to develop a method that 
could efficiently target all the drugs while minimizing as much time, effort, and solvent 
use as possible. Method validation of each technique was done for both evaluation and 
comparison purposes according to the American Academy of Forensic Science Standards 
Board final draft of Standard Practices for Method Validation in Forensic Toxicology.38 
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Evaluated parameters include calibration model, bias and precision, matrix recovery, limit 
of detection, limit of quantitation, carryover, dilution integrity, ionization 
suppression/enhancement, and stability.   
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2. MATERIALS AND METHODS 
2.1. Materials 
2.1.1. Standards and Reagents  
Drug and deuterated standards were purchased from Cerilliant (Round Rock, 
Texas, U.S.A), Cayman Chemical Company (Ann Arbor, Michigan, U.S.A.), and Toronto 
Research Chemicals (North York, Ontario, Canada). Table 1 contains the list of drugs, lot 
numbers, and source of purchase. Optima grade methanol (MeOH), optima grade 
acetonitrile (ACN), optima grade isopropanol (2-proponal, IPA), optima grade methylene 
chloride/dichloromethane (DCM) and American Chemical Society (ACS) certified 
ammonium hydroxide (NH4OH) were purchased from Fischer Scientific (Fair Lawn, New 
Jersey, U.S.A). ACS reagent grade glacial acetic acid, anhydrous sodium phosphate dibasic 
(Na2HPO4), and sodium phosphate monobasic monohydrate (H2NaO4P*H2O) were 
purchased from Acros Organics (New Jersey, U.S.A). All deionized (DI) water used during 
this research was Milli-Q water from an Ultrapure (type 1) water system from Millipore 
Sigma (Burlington, Massachusetts, U.S.A). 1% ammonium hydroxide aqueous, 1% 
hydrochloric acid in methanol, 100 mM (millimolar) phosphate buffer (pH 6.0), 100 mM 
glacial acetic acid, 78/20/2 (v/v/v) DCM/IPA/NH4OH, and 95/5 (v/v) DCM/IPA reagents 
were made in the laboratory. 0.1% formic acid in water and 0.1% formic acid in ACN were 
prepared to use as mobile phases A and B. 
Table 1: Lot Numbers for Drug Standards 
Compound Lot # 
Amphetamine FE05241804  
Methamphetamine FE08101708  
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Compound Lot # 
MDA FE03161701 0523071 
MDEA FE04021801  
MDMA 0518489  
Benzoylecgonine FE01061604  
Cocaine FE07191702  
Lidocaine FN08101706  
Codeine 0523684  
Methadone 0505453  
Morphine FE6231704  
6-MAM 0535035  
Fentanyl FE06151802  
Oxycodone  0506358  
LSD FE12141601  
PCP FE06201602  
Amitriptyline FN06131706  
Citalopram FN08141804  
Fluoxetine FN06281603  
Trazodone FN07251703  
Ethylone FE06301504  
Alpha-PVP 0517087  
25I-NBOMe 0529372  
Amphetamine-d6 FE08301801  
Methamphetamine-d5 FE03411801  
MDA-d5  FE05031601  
MDEA-d5 FE08251701  
MDMA-d5  0504233  
Benzoylecgonine-d8 FE06071702  
Cocaine-d6 0491697  
Lidocaine-d6  27-GHZ-14-1  
Codeine-d6 FE06221701  
Methadone-d9  FE01251601  
Morphine-d6 FE10241701  
6-MAM-d6 FE10061501 FE08101706 
Fentanyl-d5 FE07281604  
Oxycodone-d6 FE09201701  
LSD-d3 FE06301503  
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Compound Lot # 
PCP-d5 FE12271704  
Amitriptyline-d3 FN04151601  
Citalopram-d6 FN01301701  
Fluoxetine-d6 FN12281701  
Trazodone-d6 FN08051801  
Ethylone-d5 FE12131601   
Alpha-PVP-d8  0503495  
25I-NBOMe-d3  FE05021601  
 
2.1.2. Extraction Columns and Buffer 
ISOELUTE SLE+ (1 mL) columns were purchased from Biotage, LLC (Charlotte, 
North Carolina, U.S.A). Clean Screen® DAU (CSDAU133) SPE columns were purchased 
from United Chemical Technologies (UCT) (Bristol, Pennsylvania, U.S.A.).  Extraction 
buffer (MS-EXTBUF) was purchased from Immunalysis Corporation (Pomona, California, 
U.S.A). 
2.1.3. Specimens 
 Special Matrix (SMx) Oral Fluid was purchased from UTAK (Valencia, California, 
U.S.A). Drug-free oral fluid was donated and collected following approved Institutional 
Review Board requirements at Boston University School of Medicine Biomedical Forensic 
Science Program (Boston, Massachusetts, U.S.A.). 
2.1.4. Equipment 
 The pH of the phosphate buffer (pH 6.0) was verified using an Oakton pH 700 
meter from Fisher Scientific. Sample preparation was aided by UCT Positive Pressure 
manifold. Samples were dried down using an Organomation (Berlin, Massachusetts) 
Multivap Nitrogen Evaporator. 
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2.1.5. Instrumentation and Software 
 A Shimadzu (Kyoto, Japan) Ultra-Fast Liquid Chromatogram (UFLC) system and 
a SCIEX (Framingham, Massachusetts, U.S.A.) 4000 QTRAP tandem mass spectrometer 
with ESI was used for all analysis during the research. The column used was a Phenomenex 
(Torrance, California, U.S.A) Kinetex F5 2.6 µ 100 Å 50 x 3.0 mm.  SCIEX Analyst® 
(version 1.6.2) software was used for all data collection and SCIEX MultiQuant™ 3.0 
(version 3.0.5373.0) software was used for all quantitation. 
2.2. Methods 
2.2.1. Sample Preparation 
2.2.1.1. Biotage SLE+ 
 The following method was adapted from Courtney McGowan’s thesis project.39 
Samples were prepared in 12 x 75 millimeter (mm) test tubes. Oral fluid was vortexed with 
buffer in a 1:3 ratio for at least 15 seconds. 250 microliters (µL) of the oral fluid mixture 
was spiked with 20 µL of the appropriate working stock solution and 25 µL of 300 ng/mL 
(nanogram/milliliter) internal standard stock solution. 250 µL of 1% ammonium hydroxide 
aqueous solution (made fresh daily) was added to each sample and then vortexed for at 
least 30 seconds. 
After, samples were loaded onto the Biotage SLE+ columns using plastic pipettes. 
Pressure was applied using a bulb so that the sample can be absorbed by the bed of the 
column. The sample was absorbed by the column for 5 minutes (min). Before elution, 100 
µL of 1% hydrochloric acid in methanol (made fresh daily) was pipetted into each 
collection test tube to stabilize analytes when drying. 3 mL of elution solvent 95:5 (v:v) 
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DCM/IPA was added to columns and allowed to flow by gravity for five minutes. Another 
3 mL of elution solvent was added and allowed to flow by gravity for five minutes. Then 
positive pressure was applied to the columns 10 – 20 seconds to collect the remaining 
elution solvent. The collected eluent was dried under nitrogen at ≤ 40 oC (celcius). Dry 
samples were reconstituted with 125 µL of 0.1% formic acid in 95:5 (v:v) water:ACN and 
vortexed for at least 30 seconds. The total sample preparation technique took 
approximately 1 hour.  
Table 2: Solvent Use for SLE 
SLE Solvent Use 
Preparation 250 µL of 1% Ammonium Hydroxide 
100 µL of 1% Methanolic HCl 
Elution 6 mL of DCM/IPA 
Reconstitution 125 µL of Mobile Phase 
Total  6.475 mL 
 
2.2.1.2 UCT Clean Screen® DAU SPE  
The following method was adapted from Courtney McGowan’s thesis project.39 
Samples were prepared in 12 x 75 mm test tubes. Oral fluid was vortexed with buffer in a 
1:3 ratio for at least 15 seconds. 200 µL of the oral fluid mixture was spiked with 20 µL of 
the appropriate working stock solution and 25 µL of 300 ng/mL internal standard stock 
solution. 200 µL of 100 mM phosphate buffer (pH 6.0) was added to each sample and 
vortexed for at least 30 seconds.  
SPE columns were conditioned with 2 mL of methanol, 2 mL of deionized water, 
and 2 mL of 100 mM phosphate buffer (pH 6.0). Each solution was allowed to flow by 
gravity before the addition of the next solvent. The sample was loaded onto the columns 
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and allowed to flow by gravity.  Columns were washed with 2 mL DI water, 1 mL of 100 
mM acetic acid, and 1 mL of methanol. The column was dried via five-minute full flow, 
>25 pound-force per square inch (psi) on the vacuum manifold. Then, 3 mL of elution 
solvent 78:20:2 (v:v:v) DCM:IPA:NH4OH was added to the column on regulated flow on 
the vacuum manifold or allowed to flow by gravity. The collected eluent was dried under 
nitrogen at ≤ 40 oC. Dry samples were reconstituted with 125 µL of 0.1% formic acid in 
95:5 (v:v) water:ACN and vortexed for at least 30 seconds. The total sample preparation 
technique took approximately 2.5 hour.  
Table 3: Solvent Use for SPE 
SPE Solvennt Use 
Preparation 200 µL of 100 mM Phosphate Buffer 
Conditioning 2 mL of Methanol 
2 mL of DI Water 
2 mL of 100 mM Phosphate Buffer 
Wash 2 mL of DI Water 
1 mL of 100 mM Acetic Acid 
1 mL of Methanol 
Elution 3 mL of DCM/IPA/NH4OH 
Reconstitution 125 µL of Mobile Phase 
Total 13.325 mL 
 
2.2.2. Standard Preparation 
 Drug standards at a concentration of 1 mg/mL were purchased and used to create 
three initial working stocks at 100,000 ng/mL in methanol, which can be seen in Table 4. 
These three stock solutions were then combined and diluted to make three additional 
working stocks at 10,000 ng/mL, 1,000 ng/mL, and 100 ng/mL. These three were used to 
create solutions for spiking such as calibrators and quality controls.  
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Table 4: Stock Solution Analytes 
Stock Analytes 
Stock 1 
Amphetamine, Methamphetamine, MDA, MDEA, MDMA, 
Amitriptyline, Citalopram, Fluoxetine, Trazodone 
Stock 2 
Codeine, Methadone, Morphine, Oxycodone, 6-MAM, PCP, 
Benzoylecognine, Cocaine, Lidocaine 
Stock 3 LSD, Ethylone, Alpha-PVP, 25I-NBOMe & Fentanyl 
 
 Seven calibrations points were prepared for both SLE and SPE method validation 
at concentrations of 2, 5, 10, 25, 50, 150, and 250 ng/mL. Low, medium, and high quality 
controls were made at 6, 125, and 200 ng/mL. Additionally, working stock solutions used 
for matrix recovery, limit of detection, limit of quantitation, and dilution integrity were 
made from the three solutions mentioned earlier. 
 Deuterated drug standards were used to make the internal standard stock (ISTD). 
solution. All but lidocaine-d6 was purchased at 100 µg/mL. Lidocaine-d6 was purchased 
as a 1 mg standard therefore, 1 mL of methanol was added to create a 1 mg/mL standard. 
All deuterated compounds were combined to create an ISTD working stock solution at 300 
ng/mL.  
2.2.3. Method Validation 
 The method for SLE and SPE analysis was validated according to guidelines set by 
ASB38. The following parameters were assessed: calibration model, bias and precision, 
limit of detection, limit of quantitation, carryover, dilution integrity, interference studies, 
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ionization suppression/enhancement, and stability; matrix recovery was included as an 
additional parameter to assess. Accepted values fell within ±20% of expected values.  
2.2.3.1. Calibration Model 
 For any quantitation method, a calibration model must be determined for analytes 
of interest. The working range demonstrates that there exists a relationship between the 
signal response and analyte concentration in the sample.38 The appropriate mathematical 
model that best represents the correlation is the calibration model. At least, six calibration 
points should be included in the model; they should also be evenly distributed over the 
curve. Calibrators should be based on the expected or commonly encountered 
concentrations of day-to-day samples. A minimum of five replicates for each point must 
be analyzed.38 A simple linear regression or weighted least squares model can be used to 
best illustrate the relationship.38  
2.2.3.2. Bias and Precision 
 Bias is a measurement of how close the calculated concentration is to the known 
“true” value while precision is how close repeated measurements of the same concentration 
are to each other.38 These values were determined from the same set of data. Each of the 
five runs had its own prepared calibration curve and triplicates of low, middle, and high (6, 
125, and 200 ng/mL) quality controls. 
Acceptable values must be calculated to be within ±20% of the expected 
concentration. Bias was calculated for each concentration from every run and an average 
bias was determined.  Precision was calculated within and between each run for all 
concentrations. The following equations used: 
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2.2.3.3. Matrix Recovery 
 Matrix recovery evaluates the efficiency of the extraction method for the analyte of 
interest. Pre-extraction and post-extraction spiked samples at low (20 ng/mL) and high 
(175 ng/mL) concentrations were assessed. The equation used to calculate matrix recovery 
can be seen below: 
Recovery (%) =  - -  . /
	 0$	1- -  . /
	 0$	1  100 
2.2.3.4. Ionization Suppression/Enhancement 
 Analytes of interest can undergo ionization suppression/enhancement from co-
eluting compounds.38 Neat standards at low (20 ng/mL) and high (175 ng/mL) 
concentrations were injected six times alongside duplicates of ten different lots of matrix 
spiked post-extraction. The equation used to calculate ionization suppression/enhancement 
can be seen below:  
Ionization Supression Enchancement⁄ (%) =  - -  @ 0- -  . /
	 0$	1 − 1 100 




2.2.3.5. Limit of Detection and Limit of Quantitation 
The limit of detection is the lowest concentration that can be reliably distinguished 
from the blank matrix and identified by the method.38 For three different lots of matrix, a 
calibration curve, series of duplicate low concentration samples, and duplicate double 
blanks were analyzed; quality control samples were also included. The LOD samples were 
at concentrations: 0.05, 0.1, 0.5, 1, and 2 ng/mL. LOD was determined by the concentration 
that reliably yielded a signal greater than “the average signal of the blank samples plus 3.3 
times the standard deviation.”38 The lowest concentration that can be reliably measured 
while having acceptable identification, bias, and precision is the limit of quantitation.38  
2.2.3.6. Carryover 
 Carryover is the detection of unwanted analyte in a sample after the analysis of a 
positive sample.38 It should be assessed for both qualitative and quantitative methods to 
ensure accurate and reliable results. To evaluate the presence of carryover, a blank matrix 
sample was analyzed after the highest calibration point. Carryover was present if a signal 
greater than 10% of the lowest calibrator was detected in the blank matrix sample. 
2.2.3.7. Dilution Integrity 
 Since it is possible to test samples that are outside of the established calibration 
curve, dilutions are necessary for accurate analysis. Two common dilutions (1:10 and 1:50) 
in triplicate with bias and precision calculations were evaluated to assess dilution integrity.  
2.2.3.8. Interference Studies 
 Samples that contain compounds that are not target analytes can lead to interference 
in detection, identification, and quantification. Interfering compounds can include matrix 
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components, other drugs and metabolites, and internal standard.38 Matrix interference was 
assessed. Three mixes, listed in Table 5, containing drugs commonly found in forensic 
toxicology casework were analyzed. Interference from product ions of drugs used and 
internal standards were also assessed.  
 First, the matrix was tested to see if it interfered with any of the compounds. Ten 
different lots were tested and did not cause any false positives for either method. Drug-free 
oral fluid spiked only with internal standard was analyzed next. To check if drug ions 
interfered with their internal standard ions, the highest calibration point was run without 
any internal standard. Lastly, three mixes that contain commonly encountered drugs in 
forensic casework was spiked into drug-free oral fluid.  
Table 5: Mixes Used for Interference Assessment 




Clonazepam Butalbital 11-Hydroxy-Δ9-THC 
7-aminoclonazepam Phenobarbital 11-nor-9-Carboxy-Δ9-THC 
Diazepam  AB-FUBINACA 
Etizolam  AB-FUBINACA metabolite 3 
Hydrocodone  AB-FUBINACA metabolite 2a 
Norcocaine  AB-PINACA 
  AB-PINACA pentatonic acid metabolite 
  
2.2.3.9. Stability 
Under certain circumstances, processed samples may not always be processed 
within the ideal time frame. It is important to evaluate how long a processed sample can be 
retained before it cannot be detected, identified, or accurately and reliably quantified.38 
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Triplicate samples of low, medium, and high quality controls were assessed at the 0, 24, 
48, and 72 hour time points. Samples were stored in the chilled autosampler of the LC 
while in between time points. At each time point, the analyte signal ratio to the internal 
standard was compared to the ratio at the zero hour. 
2.2.4. LC-QTRAP Instrument Parameters 
 UFLC (Shimadzu, Kyoto, Japan) paired with a 4000 Q-Trap Electrospray 
Ionization Tandem Mass Spectrometry (ESI/MS/MS, SCIEX, Waltham, Massachusetts, 
U.S.A.) in positive ionization mode was used for all sample analysis. The injection volume 
was 5 µL with a flow rate of 0.6 mL/min. The column was a Kinetex F5 2.6 µ 100Å 50 x 
3.0 mm column (Phenomenex, Torrance, California, USA). A binary gradient of 0.1% 
Millipore water and acetonitrile was used for analysis. The gradient used during the LC 
method can be seen in Table 6. 
Table 6: LC Binary Gradient 
Time (min) %A %B 
0.01 90 10 
0.50 90 10 
3.00 80 20 
5.00 60 40 
6.50 30 70 
7.50 0 100 
9.00 0 100 
9.01 95 5 
10.00 Stop 
  
Mass spectrometry parameters were determined through optimization of each 
analyte.39 The following instrument settings were used: curtain gas 25 psi, collision gas 
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high, ion spray voltage 2500 voltage (V), temperature 550oC, and ion source gas 1 at 245.0 
psi. An entrance potential voltage of 10 V was used for all analytes. Each analyte had a 
product ion for quantitation (quant) and a second ion for qualitative (qual) assessment while 
deuterated compounds had one product ion. Declustering potential (DP), collision energy 
(CE), and cell exit potential (CXP) values for all compounds are listed in Table 7.  









CE (V) CXP (V) 
Amphetamine qual 136.1 119.3 40 12.61 20.07 
Amphetamine quant 136.1 91 40 22.16 15.7 
Amphetamine-d6 142.2 93.1 40 21.31 15.41 
Methamphetamine quant 150.1 91.1 51 25 16 
Methamphetamine qual 150.1 119.3 51 15 10 
Methamphetamine-d5 155.1 92.2 51 27 6 
MDA qual 180.1 105.2 41 35 8 
MDA quant 180.1 135.2 41 29 10 
MDA-d5 185.1 168.1 26 15 10 
MDEA quant 208.2 163.1 58 18.27 27.1 
MDEA qual 208.2 135.3 58 29.71 22.9 
MDEA-d5 213.2 163 57 19.15 27.17 
MDMA quant 194.1 163.2 40 18 12 
MDMA qual 194.1 133.1 40 28 10 
MDMA-d5 199.1 165.2 61 19 14 
Benzoylecgonine quant 290.1 168.1 70 27.93 29.12 
Benzoylecgonine qual 290.1 77.3 70 79.72 13.61 
Benzoylecgonine-d8 298.2 171.4 75 28.81 29.37 
Cocaine quant 304.1 182 96 29 14 
Cocaine qual 304.1 76.9 96 87 12 
Cocaine-d3 307.1 185 76 29 16 
Lidocaine quant 235.2 86.1 60 25.26 14.65 
Lidocaine qual 235.2 58.1 60 52.43 8.66 
Lidocaine-d6 241.2 86.2 60 25.26 14.65 
Codeine qual 300.3 115.3 95 101.6 17.56 










CE (V) CXP (V) 
Codeine-d6 306.2 152.2 100 89.56 25.15 
Methadone qual 310.3 265.3 60 21.02 47.82 
Methadone quant 310.3 105.2 60 38.3 17.23 
Methadone-d9 319.3 105.1 66 39 17.27 
Morphine quant 286.3 152.1 91 99 12 
Morphine qual 286.3 115.2 91 101 18 
Morphine-d6 292.3 152 85 80.93 25.49 
Fentanyl qual 337.2 188.3 86 33 14 
Fentanyl quant 337.2 105.1 86 55 16 
Fentanyl-d5 342.2 105.2 90 55.74 17.21 
Oxycodone quant 316.2 298.5 80 26.81 23.57 
Oxycodone qual 316.2 241.3 80 41.15 38.73 
Oxycodone-d6 322.1 304.1 80 26.61 17.89 
LSD quant 324.3 223.3 80 32.13 37 
LSD qual 324.3 207.3 80 56.52 34.92 
LSD-d3 327.3 226.3 85 33.36 37.46 
PCP quant 244.2 86.2 46 17.29 14.39 
PCP qual 244.2 91.1 46 41.39 15.69 
PCP-d5 249.2 86.2 45 18.06 14.43 
Amitriptyline quant 278.1 91 74 37.13 14.36 
Amitriptyline qual 278.1 117.1 74 30.71 20.53 
Amitriptyline-d3 281.2 91.3 75 36.14 14.76 
Citalopram quant 325.2 109.1 80 37.19 17.12 
Citalopram qual 325.2 262.4 80 27.35 43.87 
Citalopram-d6 331.3 109.2 90 36.06 18.48 
Fluoxetine quant 310.3 44.2 52 43.15 6.22 
Fluoxetine qual 310.3 148.4 52 12.3 25.14 
Fluoxetine-d6 316.3 44.2 60 43.28 5.84 
Trazodone quant 372.3 176.2 85 34.56 31.16 
Trazodone qual 372.3 148.2 85 48.71 24.7 
Trazodone-d6 378.2 182.3 86 35.58 30.33 
6-MAM quant 328 165.3 100 54.25 29.53 
6-MAM qual 328 152.1 100 93.16 25.84 
6-MAM-d6 334.1 211.1 100 37.02 35.28 
Ethylone qual 222.2 204.2 64 26.3 29.46 










CE (V) CXP (V) 
Ethylone-d5 227.2 179.1 64 28.25 30.46 
Alpha-PVP qual 232.3 126.2 70 37.1 20.48 
Alpha-PVP quant 232.3 91.2 70 31.78 15.79 
Alpha-PVP-d8 240.1 77.1 88 71.33 12.22 
25I-NBOMe quant 428.1 121.2 74 32.15 20.4 
25I-NBOMe qual 428.1 91.1 74 73 14.17 
25I-NBOMe-d3 431.1 124.2 125 53 10 
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3. RESULTS AND DISCUSSION 
3.1. Calibration Model 
 An appropriate calibration model is necessary for the validation of any method and 
future analysis. A calibration model represents the correlation between the instrument 
signal response and analyte concentration based on the working range.38  
 Working ranges are typically determined by looking at expected or commonly 
encountered drug concentrations. The same working range was used for all analytes and 
for both supported liquid extraction and solid phase extraction methods. Seven calibration 
points were used at 2, 5, 10, 25, 50, 150, and 250 ng/mL. All compounds except for 
codeine, morphine, and 6-acetylmorphine were determined to have a quadratic fit with 
A
B 
weighting. Codeine, morphine, and 6-MAM have a linear fit with 
A
B weighting.  
 The average correlation coefficient was calculated for each analyte and method. 
These values are listed in Table 8. R2 values for every analyte and method were all above 
0.99 or greater. Solid phase extraction generated more calibration curves with a R2 value 
of 0.999 or greater than supported liquid extraction. Amphetamine is used as the example 








Figure 1: SLE Calibration Curve for Amphetamine 
 
 
Figure 2: SPE Calibration Curve for Amphetamine (SPE) 
 
 
Table 8: Average Calibration Model Correlation Coefficient (R2) Values  
Compound SLE Average R2 SPE Average R2 
Amphetamine 0.99999 0.99924 
Methamphetamine 0.99929 0.99927 
MDA 0.99992 0.99970 
MDEA 0.99787 0.99937 
MDMA 0.99977 0.99885 
Benzoylecgonine 0.99878 0.99963 
Cocaine 0.99885 0.99947 
Lidocaine 0.99954 0.99931 
Codeine 0.99922 0.99621 
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Compound SLE Average R2 SPE Average R2 
Methadone 0.99678 0.99821 
Morphine 0.99794 0.99967 
Fentanyl 0.99889 0.99941 
Oxycodone 0.99982 0.99900 
6-MAM 0.99881 0.99912 
LSD 0.99892 0.99795 
PCP 0.99879 0.99902 
Amitriptyline 0.99962 0.99904 
Citalopram 0.99828 0.99921 
Fluoxetine 0.99919 0.99853 
Trazodone 0.99986 0.99980 
Ethylone 0.99899 0.99948 
Alpha-PVP 0.99971 0.99964 
25I-NBOMe 0.99894 0.99905 
 
3.2. Bias and Precision  
 According to ASB guidelines, bias is a measurement of how close the calculated 
concentration is to the known “true” value while precision is how close repeated 
measurements of the same concentration are to each other.38 Both were determined from 
the same set of five separate calibration curves with triplicates of low, middle, and high 
concentration (6, 125, and 200 ng/mL) quality controls.  
 Values for both parameters must be within 20% of expected concentrations. Table 
9 contains bias calculated for low, middle, and high quality controls. All values were within 
20% for SLE and SPE analysis. Average within, between, and grand run precision values 
are in Table 10. All, except citalopram, were found to be <20%. The SPE method for 
citalopram yielded a 20.87% for the average between run. Average bias values were similar 
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between the two methods. Average within and between precision values for both methods 
were comparable but SLE generally had lower values for grand run precision. 
Table 9: Average Bias Values  
Compound 
SLE Bias SPE Bias 
L M H L M H 
Amphetamine 0.83 2.97 1.50 0.25 1.15 0.83 
Methamphetamine -0.37 4.19 2.67 1.83 0.64 0.77 
MDA -1.14 -2.61 -5.25 0.27 -0.15 4.11 
MDEA 0.32 5.74 6.25 1.57 3.92 0.74 
MDMA 1.54 4.74 4.46 0.28 1.94 2.05 
Benzoylecgonine -1.36 1.64 2.31 -1.45 3.38 5.25 
Cocaine -1.04 6.93 7.70 -1.08 6.71 1.25 
Lidocaine -4.25 -1.65 2.49 2.81 8.15 8.22 
Codeine -0.22 2.84 2.98 6.12 1.10 2.94 
Methadone -0.52 4.30 6.14 5.00 2.68 7.20 
Morphine 2.06 4.52 -0.39 -1.80 0.31 4.80 
Fentanyl 1.64 6.18 3.18 2.73 1.85 4.17 
Oxycodone -2.04 5.88 2.41 2.88 0.02 5.35 
6-MAM 4.46 0.76 4.77 3.44 -2.43 2.78 
LSD 4.62 2.73 4.40 0.22 1.55 6.85 
PCP 1.30 1.13 3.18 1.13 3.26 3.97 
Amitriptyline 2.41 0.27 7.48 2.27 1.73 -2.05 
Citalopram 0.78 6.12 8.73 1.79 3.05 
-
11.09 
Fluoxetine 1.67 5.24 1.33 7.00 5.58 0.74 
Trazodone -0.17 4.44 1.77 5.10 2.60 4.53 
Ethylone 3.78 -0.10 -0.89 2.72 1.33 6.00 
Alpha-PVP 3.87 4.53 3.04 0.04 3.41 -0.66 
25I-NBOMe -4.59 4.68 4.25 -3.96 2.16 4.41 
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SLE SPE SLE SPE SLE SPE 
Amphetamine 6.05 7.13 7.44 11.26 7.52 11.01 
Methamphetamine 6.80 9.12 9.04 13.83 9.25 14.31 
MDA 7.36 11.37 10.22 14.73 10.52 15.33 
MDEA 5.81 5.06 8.53 7.80 8.82 7.79 
MDMA 6.39 7.27 8.38 8.99 8.25 8.84 
Benzoylecgonine 7.94 5.60 10.13 10.18 10.31 10.42 
Cocaine 5.69 6.60 6.99 7.94 7.82 7.85 
Lidocaine 6.21 11.36 7.42 14.42 7.85 16.74 
Codeine 7.85 6.79 12.51 8.62 12.28 8.77 
Methadone 4.79 7.59 11.18 11.54 9.09 11.42 
Morphine 8.34 8.86 12.77 12.50 13.27 12.66 
Fentanyl 5.49 10.12 10.81 13.14 10.44 13.59 
Oxycodone 8.56 9.40 9.46 15.07 9.56 15.43 
6-MAM 9.02 6.87 11.96 7.59 11.26 8.20 
LSD 6.53 8.08 9.74 10.37 9.60 10.66 
PCP 5.20 5.75 7.50 9.31 7.51 9.61 
Amitriptyline 5.79 11.60 7.45 12.26 7.98 12.58 
Citalopram 6.63 11.62 7.87 20.87 7.86 27.79 
Fluoxetine 6.77 11.83 7.91 14.41 8.05 14.37 
Trazodone 5.31 9.24 8.95 12.44 8.87 12.38 
Ethylone 6.65 10.01 8.63 13.73 8.63 14.81 
Alpha-PVP 5.30 6.81 8.66 9.59 8.51 9.74 
25I-NBOMe 6.25 7.47 9.30 9.53 9.99 10.00 
 
3.3. Matrix Recovery 
 Matrix recovery details the efficiency of the extraction method for each analyte. 
Pre-extraction and post-extraction spiked samples at low (20 ng/mL) and high (175 ng/mL) 
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concentrations were assessed. The % recoveries for low and high concentrations are listed 
in Table 11.  
 Most recovery values for SLE and SPE were between 80-120%; some values were 
outside this accepted range. SLE had better recovery values than SPE. For SPE, the 
recovery values for antidepressants were not as high as those of SLE. LSD and PCP could 
not be recovered well by either method.  
Table 11: Matrix Recovery Values 
Compound 
SLE %Recovery SPE %Recovery 
Low High Low High 
Amphetamine 110.86 107.29 98.14 105.30 
Methamphetamine 113.86 94.60 77.37 105.91 
MDA 93.45 109.23 112.01 118.99 
MDEA 120.20 103.71 92.57 101.49 
MDMA 114.96 95.86 93.81 107.81 
Benzoylecgonine 131.84 108.81 74.11 80.45 
Cocaine 104.35 122.06 85.49 87.46 
Lidocaine 108.60 99.26 101.66 91.45 
Codeine 106.06 104.06 121.53 119.51 
Methadone 121.46 98.05 108.77 98.98 
Morphine 125.47 100.15 108.19 114.15 
Fentanyl 122.18 103.00 58.08 70.11 
Oxycodone 109.81 95.89 104.33 119.42 
6-MAM 100.93 97.95 76.81 124.22 
LSD 66.58 75.65 46.21 55.81 
PCP 57.02 67.45 63.27 67.22 
Amitriptyline 101.41 84.49 50.16 33.62 
Citalopram 111.44 85.94 46.53 52.35 
Fluoxetine 100.97 81.52 45.75 36.44 
Trazodone 113.91 107.05 51.53 55.29 
Ethylone 138.27 109.74 99.92 121.46 
Alpha-PVP 143.21 98.71 83.16 81.97 
25I-NBOMe 94.21 105.70 86.01 33.93 
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3.4. Ionization Suppression/Enhancement 
 Ionization suppression and enhancement occur from co-eluting compounds from 
the matrix or extraction method. Neat standards at low (20 ng/mL) and high (175 ng/mL) 
concentrations were injected six times alongside duplicates of ten different lots of matrix 
spiked post-extraction, a calibration curve, and quality controls. Data within a method can 
be affected since it relies on analyte signal.  Values can be seen in Table 12 Ionization 
suppression/enhancement values were better for SLE than for SPE. For both methods, 
compounds generally experienced suppression rather than enhancement. For SPE, the 
antidepressants had high values of suppression compared to that of SLE.  







Low High Low High 
Amphetamine -11.27 -11.35 0.44 -5.50 
Methamphetamine -9.01 -10.02 10.89 -5.98 
MDA 9.72 0.21 -9.38 -7.93 
MDEA -5.26 -15.66 -4.86 -1.4 
MDMA -3.40 -9.96 -7.05 -5.07 
Benzoylecgonine -4.70 -0.76 -0.61 -2.36 
Cocaine -14.99 -26.03 -30.16 -20.09 
Lidocaine -8.03 -5.40 -17.66 -0.92 
Codeine -9.70 -7.61 -10.37 7.31 
Methadone -3.90 -0.07 -54.90 -28.25 
Morphine 4.09 -9.95 -36.74 -21.60 
Fentanyl 5.07 -12.86 -60.25 -48.03 
Oxycodone 2.31 -0.84 2.86 8.06 
6-MAM -1.94 -3.97 1.25 -32.56 
LSD 7.89 -5.93 -56.13 -41.58 
PCP -18.39 -13.99 -41.33 -18.04 








Low High Low High 
Citalopram -22.04 -16.72 -59.85 -35.77 
Fluoxetine -1.35 -4.12 -73.69 -55.47 
Trazodone 6.22 -14.28 -64.88 -45.91 
Ethylone -15.77 -5.06 -2.92 5.73 
Alpha-PVP -11.71 -6.61 -19.59 -11.45 
25I-NBOMe -8.83 -13.32 -75.27 -60.50 
 
3.5. Limit of Detection and Limit of Quantitation 
The limit of detection is the lowest concentration that can be consistently 
distinguished and identified from the blank matrix by the method.38 For three different lots 
of matrix, a calibration curve, series of duplicate low concentration samples, and duplicate 
double blanks were analyzed; quality control samples were also included. The LOD 
samples were at concentrations: 0.05, 0.1, 0.5, 1, and 2 ng/mL. Peak shape was also 
assessed to ensure that it was distinguishable from the base line. Table 13 contains LOD 
values. Both SLE and SPE methods yielded similar LOD values. Some compounds like 
lidocaine and codeine may extract better with SLE while others like methadone and 
amitriptyline are better with SPE.  
Table 13: Limit of Detection Values 
Compound SLE SPE 
Amphetamine 0.1 0.1 
Methamphetamine 0.5 0.5 
MDA 0.5 0.5 
MDMA 0.5 0.5 
MDEA 1 1 
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Compound SLE SPE 
Benzoylecgonine 1 1 
Cocaine 0.5 0.5 
Lidocaine 1 2 
Codeine 0.5 2 
Methadone 1 0.5 
Morphine 0.5 1 
Fentanyl 0.5 1 
Oxycodone 0.5 1 
6-MAM 1 0.5 
LSD 0.5 2 
PCP 0.5 1 
Amitriptyline 0.1 0.5 
Citalopram 0.5 0.5 
Fluoxetine 0.5 0.5 
Trazodone 0.1 0.5 
Ethylone 0.5 1 
Alpha-PVP 1 1 
25I-NBOMe 2 2 
 
The lowest concentration that can be reliably measured while having acceptable 
identification, bias, and precision is the limit of quantitation.38 A calibration curve and 
series of duplicate low concentration samples in three different lots of matrix were used to 
assess LOQ. LOQ values were determined as the concentration which had average 
calculated concentration accuracy between 80-120%. Table 14 has the values of LOQ for 





Table 14: Limit of Quantitation Values 
Compound SLE SPE 
Amphetamine 0.1 0.5 
Methamphetamine 1 1 
MDA 0.5 1 
MDEA 1 2 
MDMA 0.5 1 
Benzoylecgonine 2 2 
Cocaine 1 0.5 
Lidocaine 2 2 
Codeine 1 2 
Methadone 2 1 
Morphine 2 1 
Fentanyl 0.5 1 
Oxycodone 1 1 
6-MAM 2 1 
LSD 0.5 2 
PCP 0.5 2 
Amitriptyline 0.5 1 
Citalopram 0.5 0.5 
Fluoxetine 1 0.5 
Trazodone 0.5 0.5 
Ethylone 1 2 
Alpha-PVP 1 1 
25I-NBOMe 2 2 
 
3.6. Carryover 
 Carryover is the presence of unwanted analyte in samples preceding positive 
analysis. It was seen with several drugs for both SLE and SPE methods. Methadone and 6-
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MAM carryover was present in SPE but not SLE. For SLE, 25I-NBOMe had carryover. 
For both methods, fentanyl carryover was present.  
 Following a high concentration sample with solvent blank is recommended and 
more can be run as necessary. Another solution is to add a longer 100% organic mobile 
phase period at the end of the method to aid in complete elution of compounds. 
3.7. Dilution Integrity 
 Dilution of samples may be necessary when their concentrations are outside of the 
working range. Precision was assessed after dilution. Two common dilutions (1:10 and 
1:50) in triplicate were analyzed five times alongside five separate calibration curves. Table 
15 lists values for each analyte. Most of the values for the dilutions were within ±20%. 
Morphine 1:50 dilution for SLE and 25I-NBOMe 1:10 dilution for SPE did not meet the 
accepted values (bolded in table below). Both SLE and SPE methods yielded similar 
precision values but SLE had slightly lower numbers. 






Figure 4: SLE 1:50 Dilution of Amphetamine 
 
 
Figure 5: SPE 1:10 Dilution of Amphetamine 
 
 





Table 15: Dilution Integrity Precision Values 
Compound 
%CV for SLE %CV for SPE 
1:10 1:50 1:10 1:50 
Amphetamine 8.72 6.73 5.10 5.36 
Methamphetamine 5.50 4.88 5.67 6.08 
MDA 4.68 7.53 6.54 4.20 
MDEA 7.15 9.47 3.97 5.14 
MDMA 7.26 4.52 5.71 5.76 
Benzoylecgonine 6.91 7.38 5.89 5.55 
Cocaine 5.77 5.56 7.82 5.45 
Lidocaine 4.96 3.54 4.43 7.33 
Codeine 7.81 9.77 4.16 6.40 
Methadone 9.02 3.95 6.74 5.67 
Morphine 6.91 31.48 4.01 4.06 
Fentanyl 6.47 4.60 8.52 5.10 
Oxycodone 9.60 9.12 6.73 4.66 
6-MAM 7.64 14.08 7.49 4.78 
LSD 5.15 4.60 8.73 4.89 
PCP 5.07 7.30 8.85 7.53 
Amitriptyline 4.29 6.06 5.46 7.25 
Citalopram 5.28 3.77 5.11 5.24 
Fluoxetine 7.46 6.61 5.79 10.26 
Trazodone 4.99 3.15 7.43 13.18 
Ethylone 6.87 4.29 7.05 6.28 
Alpha-PVP 9.07 6.03 6.38 5.35 
25I-NBOMe 4.37 3.55 20.68 4.58 
 
3.8. Interference Studies 
 Interferences are the presence of compounds that are not specifically targeted by 
the method.38 This can affect the integrity to detect, identify, and quantitate an analyte of 
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interest. Commonly encountered drugs, matrix, target analyte ions, and internal standard 
ions can all be sources of interference.  
 To check if the matrix could interfere with the analytes, ten different lots of double 
blanks were assessed. No interferences were seen with either method. Then drug-free 
matrix with only internal standard was analyzed and no interferences were found. The 
highest calibration standard was analyzed without adding any internal standard; ions from 
PCP were discovered to interfere with PCP-d5. Lastly, three mixes were spiked into drug-
free oral fluid. Compounds in each of the three mixes can be seen in Table 3. Norcocaine, 
a metabolite of cocaine, interfered with cocaine; they had the same transitions and retention 
times. Additionally, hydrocodone was found to interfere with codeine; they also had the 
same transitions and eluted at similar times.  
3.9. Stability 
 Stability is important to consider when samples cannot be run immediately. 
Average values of drug to internal standard ratio at 24, 48, and 72 hours were compared to 
value at 0 hours and accepted if they fell within ±20% of the expected range. For both 






 This study compared supported liquid extraction and solid phase extraction for the 
detection and quantitation of twenty-three different drugs. These two methods were 
assessed through method validation results. Guidelines set by ASB were used.38 All drugs 
were validated for both SLE and SPE. Overall, SLE was the preferred method of extraction 
for all classes of drugs.  
 Matrix recovery and ionization suppression/enhancement varied greatly between 
the two methods. Recovery values were generally higher for SLE than SPE. For SLE, most 
value were between the acceptable values of 80 – 120%. SPE had more compounds that 
did not have acceptable recovery values. The antidepressants, in particular, did not extract 
very well for SPE; they also experienced high ion suppression following SPE. Both LSD 
and PCP did not extract to acceptable standards from either method. Although recovery 
was low, LSD and PCP had results for bias, precision, and dilution integrity that fell within 
acceptable values. Since ion suppression/enhancement can affect the results and 
interpretation of other parameters, it is important to develop a method that can provide 
acceptable values. Most SLE values for ionization suppression/enhancement were within 
±20% but many drugs exceeded ±20% for SPE.  
 Limit of detection and quantitation values were similar between SLE and SPE. SLE 
did have slightly lower values for both LOD and LOQ. Sample preparation technique did 
not greatly affect parameters such as the calibration model, stability, interferences, and 
carryover. Bias, precision, and dilution integrity values were also similar between the 
methods.  
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 Furthermore, it is important to consider both the time and cost of each sample 
preparation technique. SLE took approximate 1 hour while SPE took roughly 2.5 hours due 
to additional conditioning and wash steps. SLE cartridges were also more expensive than 
SPE cartridges; one SLE cartridge was approximately $2.50 while a single SPE cartridge 
cost about $1.74. SPE, however, has added costs due to heavy solvent use when 
conditioning, washing, and eluting. Based on the overall results, SLE is determined to be 
the preferred method of sample preparation due to its ease of use, speedier extraction, and 
better results.  
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5. FUTURE RESEARCH 
A possible area for further research is to collect oral fluid donations using kits such 
as Quantisal®, Accu·Sal™, or Intercept®. In this project, oral fluid was collected by 
expectorating into collection tubes. Buffer was added when starting the sample preparation 
technique. In the field, oral fluid is collected using the kits and some even have buffer 
already added. Utilizing these kits most closely mimic these conditions. The effect of buffer 
can also be explored since it could lead to better or worse extraction of certain compounds. 
Another future direction is to study different groups of drugs that are not already included 
or even add them to the current method. Other drugs classes to consider include synthetic 
and natural cannabinoids, benzodiazepines, and barbiturates. Additionally, different brands 
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